News & Perspective

Sep 09, 2008

Sep 09, 2008

HHS funds work on new anthrax antitoxin

(CIDRAP News) – Emergent BioSolutions Inc. recently announced that it won a federal contract worth $24.3 million to develop a monoclonal antibody treatment to block the effects of anthrax toxin.

Nov 04, 2004

Nov 04, 2004

HHS to spend $877 million on new anthrax vaccine

Editor's note: A correction was made in this story Nov 9 to note that the existing licensed anthrax vaccine contains the natural rather than recombinant form of anthrax protective antigen.

(CIDRAP News) – Federal health officials today announced the award of an $877 million contract for 75 million doses of a new anthrax vaccine to protect the public and improve on the existing vaccine used by the military.